MedTrace Logo

Safety and Effectiveness of the Calhoun Vision Light Adjustable Intraocular Lens (LAL)

NCT00845520 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2018-07-06

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate, for the visual correction of aphakia, the safety and effectiveness of the Calhoun Vision Light Adjustable intraocular lens (LAL) and Light Delivery Device (LDD) in treating postoperative residual refractive error by providing a stable, targeted refractive adjustment of the LAL power and lock-in treatments with the LDD.

Conditions

  • Cataracts

Interventions

DEVICE

Lens implantation +1.00 D postop target

Lens implantation +1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.

DEVICE

Lens implantation -1.00 D postop target

Lens implantation -1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.

DEVICE

Lens implantation 0.00 D postop target

Lens implantation 0.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.

Sponsors & Collaborators

  • Calhoun Vision, Inc.

    lead INDUSTRY

Principal Investigators

  • R. Doyle Stulting, MD, PhD · Emory Eye Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States
  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00845520 on ClinicalTrials.gov